A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome

Trial Profile

A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs ADX 102 (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions
  • Sponsors Aldeyra Therapeutics
  • Most Recent Events

    • 10 Oct 2017 According to an Aldeyra Therapeutics media release, data will be presented at the 2017 Research & Development Day.
    • 12 Sep 2017 Results published in an Aldeyra Therapeutics media release.
    • 11 Sep 2017 According to an Aldeyra Therapeutics media release, company will shedule webcast and conference call to announce results from this study on September 12, 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top